Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1444-1449

  Ulusoy, Sukru ^a   Ozkan, Gulsum ^a   Menteşe, Ahmet ^a   Yavuz, Adnan ^b   Karahan, S Caner ^a   Sümer, Ayşegül Uzun ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Trabzon RTS Hemodialysis Center   (Turkey)

Author keywords

Hemodialysis; SCD40L; SCUBE1; Signal peptide CUB EGF domain containing protein 1

Indexed keywords

C REACTIVE PROTEIN; CARNITINE; CD40 LIGAND; CREATININE; SCUBE 1 PROTEIN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENDER; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL;

AGED; CARNITINE; CASE-CONTROL STUDIES; CD40 LIGAND; CREATININE; ERYTHROPOIETIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RENAL DIALYSIS; VITAMIN B COMPLEX;

EID: 84868300118     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.103     Document Type: Article

References (28)

1. Yang R.B., Ng C.K., Wasserman S.M., Colman S.D., Shenoy S., Mehraban F., et al. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J Biol Chem 2002, 277:46364-46373.
2. Grimmond R.Larder, Van Hateren N., Siggers P., Morse S., Hacker T., Arkell R., et al. Expression of a novel mammalian epidermal growth factor-related gene during mouse neural development. Mech Dev 2001, 102:209-211.
3. Haworth K., Smith F., Zoupa M., Seppala M., Sharpe P.T., Cobourne M.T. Expression of the Scube3 epidermal growth factor-related gene during early embryonic development in the mouse. Gene Expr Patterns 2007, 7:630-634.
4. Tu C.F., Su Y.H., Huang Y.N., Tsai M.H., Li L.T., Chen Y.L., et al. Localization and characterization of a novel secreted protein SCUBE1 in human platelets. Cardiovasc Res 2006, 71:486-495.
5. Tu C.F., Yan Y.T., Wu S.Y., Djoko B., Tsai M.T., Cheng C.J., et al. Domain and functional analysis of a novel platelet-endothelial cell surface protein, SCUBE1. J Biol Chem 2008, 283:12478-12488.
6. Dai D.F., Thajeb P., Tu C.F., Chiang F.T., Chen C.H., Yang R.B., et al. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. J Am Coll Cardiol 2008, 51:2173-2180.
7. Collins A.J. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003, 325:163-167.
8. Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
9. Milburn J.A., Cassar K., Ford I., Fluck N., Brittenden J. Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis. Int J Artif Organs 2011, 34:280-287.
10. Elshamaa M.F., Elghoroury E.A., Helmy A. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia. Blood Coagul Fibrinolysis 2009, 20:230-239.
11. Waki K., Hayashi A., Ikeda S., Ikeda S., Nagatsuka K., Honma Y., et al. Measuring platelet aggregation in dialysis patients with a whole blood aggregometer by the screen filtration pressure method. Ther Apher Dial 2011, 15:203-206.
12. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006, 48:2-90.
13. Carvalho A.C. Acquired platelet dysfunction in patients with uremia. Hematol Oncol Clin North Am 1990, 4:129-143.
14. Sloand J.A., Sloand E.M. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997, 8:799-803.
15. Moal V., Brunet P., Dou L., Morange S., Sampol J., Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003, 18:1834-1841.
16. Lim P.S., Wu M.Y., Chien S.W., Wu T.K., Liu C.S., Hu C.Y., et al. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease. Nephrology (Carlton) 2008, 13:677-683.
17. Hollenbaugh D., Grosmaire L.S., Kullas C.D., Chalupny N.J., Braesch-Andersen S., Noelle R.J., et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992, 11:4313-4321.
18. Clark L.B., Foy T.M., Noelle R.J. CD40 and its ligand. Adv Immunol 1996, 63:43-78.
19. Desideri G., Panichi V., Paoletti S., Grassi D., Bigazzi R., Beati S., et al. RISCAVID investigators: soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrol Dial Transplant 2011, 26:2983-2988.
20. Hickman P.E. Biomarkers and cardiac disease in patients with end-stage renal disease on dialysis. Clin Biochem Rev 2011, 32:115-119.
21. Korkmaz H., Saşak G., Celik A., Kurtoǧlu E., Gürger M., Bursali K.B., et al. The comparison of cardiac biomarkers positivities in hemodialysis patients without acute coronary syndrome. Ren Fail 2011, 33:578-581.
22. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., De Backer A.L., Catapano G., Graham I., Taskinen M.R., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
23. Nadar S., Blann A.D., Lip G.Y. Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 2004, 36:552-557.
24. Peyrou V., Lormeau J.C., Hérault J.P., Gaich C., Pfliegger A.M., Herbert J.M. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999, 81:400-406.
25. Roeloffzen W.W., Kluin-Nelemans H.C., Mulder A.B., Veeger N.J., Bosman L., de Wolf J.T. In normal controls, both age and gender affect coagulability as measured by thrombelastography. Anesth Analg 2010, 110:987-994.
26. Iselin B.M., Willimann P.F., Seifert B., Casutt M., Bombeli T., Zalunardo M.P., et al. Isolated reduction of haematocrit does not compromise in vitro blood coagulation. Br J Anaesth 2001, 87:246-249.
27. Hakeshzadeh F., Tabibi H., Ahmadinejad M., Malakoutian T., Hedayati M. Effects of l-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Ren Fail 2010, 32:1109-1114.
28. Pignatelli P., Tellan G., Marandola M., Carnevale R., Loffredo L., Schillizzi M., et al. Effect of l-carnitine on oxidative stress and platelet activation after major surgery. Acta Anaesthesiol Scand 2011, 55:1022-1028.